IP Library Granted Patent US 8,383,653
Granted Patent B2
US 8,383,653 · App. 10/560,676 · Granted Feb 26, 2013

SIR2 regulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,653
App. No.
10/560,676
Granted
Feb 26, 2013
Kind
B2
Abstract

Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.

Claims (12)

1. A method of increasing protein deacetylation by a SIR2 enzyme in a living cell, the method comprising contacting the cell with isonicotinamide in an amount effective to increase protein deacetylation by a SIR2 enzyme in a living cell, wherein isonicotinamide is in a composition formulated for topical administration.

2. The method of claim 1 , wherein the cell is an archaeal cell or a prokaryotic cell.

3. The method of claim 1 , wherein the cell is part of a living organism.

4. The method of claim 1 , wherein the cell is a mouse cell.

5. The method of claim 1 , wherein the cell is a human cell.

6. The method of claim 3 , wherein the living organism is a mammal.

7. The method of claim 3 , wherein the living organism is a human.

8. The method of claim 1 , wherein the SIR2 enzyme is selected from the group consisting of SIR2A, SIRT3, SIRT2p, SIRT1p, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7.

9. A method of activating a SIR2 enzyme in a living cell, the method comprising contacting the cell with isonicotinamide in an amount effective to activate a SIR2 enzyme in a living cell, wherein isonicotinamide is in a composition formulated for topical administration.

10. The method of claim 9 , wherein the cell is in a human.

11. The method of claim 1 , wherein the composition includes one or more of propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone, ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate and polyvinyl pyrrolidone.

12. The method of claim 9 , wherein the composition includes one or more of propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone, ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate and polyvinyl pyrrolidone.

Assignments (5)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CHANGE OF NAME Recorded Oct 19, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036887/0386 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036865/0901 →
CONFIRMATORY LICENSE Recorded Jun 8, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035856/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2007
From: SCHRAMM, VERN L.; SAUVE, ANTHONY A.
To: YESHIVA UNIVERSITY, ALBERT EINSTEIN COLLEGE OF MEDICINE OF
Reel/Frame 019985/0972 →